Drugs / XTR004
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04596527 | Sep 2020 → Jun 2022 | coronary artery disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07187895 | Dec 2024 → Mar 2025 | coronary artery disorder | Sinotau Pharmaceutical Group | Terminated | No outcome recorded |
| Phase 2 | NCT05885841 | Feb 2022 → May 2023 | coronary artery disorder | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07439133 | Nov 2025 → Jun 2027 expected | coronary artery disorder | Sinotau Pharmaceutical Group | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTR004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07187895 ↗ |
| Known as | 18F-FMPP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04596527 ↗ |
| Modality | Diagnostic / imaging agent | “18F-FMPP is a novel PET myocardial perfusion imaging (MPI) tracer” NCT04596527 ↗ |
| Route | Intravenous | “All subjects will receive rest and stress IV boluses of 18F-FMPP injections in a large peripheral vein.” NCT04596527 ↗ |